Urban N - Search Results

1

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Goodell V, et al. Among authors: urban n. J Clin Oncol. 2006 Feb 10;24(5):762-8. doi: 10.1200/JCO.2005.03.2813. Epub 2006 Jan 3. J Clin Oncol. 2006. PMID: 16391298

2

Bead-based ELISA for validation of ovarian cancer early detection markers.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N. Scholler N, et al. Among authors: urban n. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24. doi: 10.1158/1078-0432.CCR-05-2007. Clin Cancer Res. 2006. PMID: 16609024 Free PMC article.

3

Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.

McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. McIntosh MW, et al. Among authors: urban n. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8. doi: 10.1158/1078-0432.CCR-06-2224. Clin Cancer Res. 2007. PMID: 17671125

4

Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW. Drescher CW, et al. Among authors: urban n. J Clin Oncol. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. Epub 2012 Dec 17. J Clin Oncol. 2013. PMID: 23248253 Free PMC article.

5

Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.

Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B. Stewart JJ, et al. Mol Cell Proteomics. 2006 Mar;5(3):433-43. doi: 10.1074/mcp.M500140-MCP200. Epub 2005 Nov 30. Mol Cell Proteomics. 2006. PMID: 16319398 Free article.

6

Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.

Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B. Pan S, et al. OMICS. 2009 Aug;13(4):345-54. doi: 10.1089/omi.2009.0008. OMICS. 2009. PMID: 19422301 Free PMC article.

7

Use of a single-chain antibody library for ovarian cancer biomarker discovery.

Ramirez AB, Loch CM, Zhang Y, Liu Y, Wang X, Wayner EA, Sargent JE, Sibani S, Hainsworth E, Mendoza EA, Eugene R, Labaer J, Urban ND, McIntosh MW, Lampe PD. Ramirez AB, et al. Mol Cell Proteomics. 2010 Jul;9(7):1449-60. doi: 10.1074/mcp.M900496-MCP200. Epub 2010 May 13. Mol Cell Proteomics. 2010. PMID: 20467042 Free PMC article.

8

Use of high density antibody arrays to validate and discover cancer serum biomarkers.

Loch CM, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, Garvik BM, Urban ND, McIntosh MW, Lampe PD. Loch CM, et al. Among authors: urban nd. Mol Oncol. 2007 Dec;1(3):313-20. doi: 10.1016/j.molonc.2007.08.004. Epub 2007 Aug 30. Mol Oncol. 2007. PMID: 19383305 Free PMC article.

9

Ovarian cancer screening.

Urban N, McIntosh MW, Andersen M, Karlan BY. Urban N, et al. Hematol Oncol Clin North Am. 2003 Aug;17(4):989-1005, ix. doi: 10.1016/s0889-8588(03)00063-7. Hematol Oncol Clin North Am. 2003. PMID: 12959188 Review.

10

Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N. Drescher CW, et al. Among authors: urban n. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15066925 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

426 results

Search Page

Filters